Regeneron's Pasatru FDA Approved, Competing with Sohonos in Adult FOP Market
Anti-Activin A Antibody Enters Adult FOP Treatment
The U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals (REGN)'s Pasatru (garetosmab-grts) on August 19, 2026, for the treatment of adult progressive fibrodysplasia ossificans (FOP). Pasatru is a fully human monoclonal antibody that neutralizes Activin A, a driver of heterotopic ossification (HO), administered intravenously once monthly at 10 mg/kg, with a dose reduction to 3 mg/kg for patients with poor tolerance. Although a rare disease with approximately 900 diagnosed patients globally, FOP causes irreversible deterioration of mobility and respiratory function as muscles and ligaments are replaced by bone, making lesion inhibition a clinically significant mechanism.
OPTIMA Phase 3 Trial Provided Approval Basis
In the randomized, double-blind, placebo-controlled OPTIMA Phase 3 trial involving 63 adults, new HO lesions over 56 weeks were 1 in the 3 mg/kg group and 2 in the 10 mg/kg group, compared to 19 in the placebo group, representing 94% and 90% reductions, respectively, with p-values of 0.0274 and 0.0260. Physician-assessed flare-ups decreased by 88% in the 10 mg/kg group (9 vs. 66 in placebo), but only by 15% in the 3 mg/kg group (53 vs. 66 in placebo), while patient-reported flare-up differences were not statistically significant. Thus, while lesion inhibition based on imaging is strong, real-world functional and quality-of-life improvements, as well as long-term safety, will determine commercial sustainability through post-marketing data.
Ipsen's Sohonos Diverges in Dosing and Evidence Level
The current standard of care is Ipsen (IPN)'s oral Sohonos (palovarotene), a retinoic acid receptor gamma (RARγ) agonist, approved by the FDA on August 16, 2023, for FOP patients aged 8 years and older in females and 10 years and older in males. At the time, the FDA advisory committee voted 10 to 4 on efficacy and 11 to 3 on benefit-risk, but the EMA rejected approval on July 17, 2023, citing unmet pre-specified endpoints and risks of premature closure of growth plates. Pasatru, limited to adults, is positioned with a placebo-controlled Phase 3 trial and high lesion inhibition rates, but faces competition due to the monthly intravenous administration burden and adverse reactions such as abscesses, acne, hirsutism, and oral ulcers.
Access Determines Revenue in Ultra-Premium Rare Disease Market
The annual cost of Pasatru ranges from approximately USD 693,000 to USD 2.1 million, averaging around USD 1.4 million, meaning insurance coverage and infusion infrastructure, rather than the number of diagnosed patients, will determine the real market size. Sohonos' first-half 2026 revenue reached about EUR 21 million, and Ipsen recognized a EUR 279 million impairment charge in 2024, reflecting lower patient adoption and projected revenue. For Regeneron, Pasatru is more of a regulatory and commercial validation asset for its rare disease platform, rather than an immediate blockbuster, amid biosimilar pressures on Eylea (aflibercept). The EMA review and the planned Phase 3 OPTIMA-2 trial in children in 2026 represent mid-to-long-term expansion pathways.
From an investment perspective, Pasatru is a commercial-stage asset targeting approximately 900 diagnosed patients with an average annual price of around USD 1.4 million, but market penetration and insurance coverage will determine revenue ceilings. For researchers, the 94% and 90% reductions in new HO lesions in the 3 mg/kg and 10 mg/kg groups in the OPTIMA Phase 3 trial establish Activin A as a validated FOP target. For the industry, the competition between FDA-approved Sohonos and Pasatru has shifted to a differentiation dynamic between oral convenience and pediatric indications versus placebo-controlled efficacy and monthly intravenous administration. Sohonos' first-half 2026 revenue of EUR 21 million highlights the currently limited commercial scale. In the short term, Pasatru adds to Regeneron's rare disease revenue base, while in the mid-to-long term, the EMA review and the success of the pediatric OPTIMA-2 Phase 3 trial will determine growth beyond the U.S. adult market and Pasatru's portfolio contribution.
Source: BioPharma Dive (rss)